Isaac Kim, MD, PhD

Isaac Y. Kim, MD, PhD

The Cancer Institute of New Jersey
195 Little Albany Street
New Brunswick, NJ 08903
Phone: (732) 235-8515
Fax: (732) 235-6596

Dr. Kim specializes in Urology.

Medical School
  • Northwestern University Medical School, Chicago, IL
Residency
  • Baylor College of Medicine, Houston, TX
Fellowship
  • University of California at Irvine College of Medical, Irvine, CA
Specialty Interests
Research Interests
  • Tumor immunology focusing on immunosuppressive factors produced by prostate cancer cells
Publications
  • Kim IY and Kim SJ. Role of bone morphogenetic proteins in transitional cell carcinoma cells (2005). Cancer Letters, in press.
  • Kim IY, Lee DH, Lee DK, Kim WJ, Kim MM, Morton RA, Lerner SP, Kim SJ (2004). Restoration of bone morphogenetic proteins receptor type II expression leads to a decreased rate of tumor growth in bladder transitional cell carcinoma cell line, TSU-Pr1. Cancer Research 64:7355-7360.
  • Kim IY, Lee DH, Ahn HJ, Kim MM, Kim SJ and Morton RA (2004). Loss of expression of bone morphogenetic protein receptor type II in human prostate cancer cells. Oncogene 23:7651-7659.
  • Shariat SF, Menesses-Diaz A, Kim IY, Muramoto M, Wheller TM, Slawin KM. (2004) Tissue expression of transforming growth factor-b1-and its receptors: correlation with pathologic features and biochemical progression in patients undergoing radical prostatectomy. Urology 63:1191-1197.
  • Kim IY, Lee DH, Lee DK, Kim BC, Kim HT, Leach FS, Linehan M, Morton RA, and Kim SJ (2003) Decreased expression of bone morphogenetic protein receptor type II correlates with insensitivity to BMP-6 in human renal cell carcinoma cells. Clinical Cancer Research 9:6046-6051.
  • Kim IY, Kim BC, Seong DH, Lee DK, Seo JM, Kim HT, Morton RA, and Kim SJ (2002). Raloxifene, a mixed estrogen agonist/antagonist, induces apoptosis in androgen-independent human prostate cancer cell lines. Cancer Research 62:5365-5369.
  • Kim HT, Kim BC, Kim IY, Mamura M, Seong DH, Jang JJ, and Kim SJ (2002). Raloxifene, a mixed estrogen agonist/antagonist, induced apoptosis through cleavage of BAD in human bladder cancer cells. Journal of Biological Chemistry 277:32510-32515.
  • Kim IY, Lee DH, Lee DK, Kim BC, Kim HT, Leach FS, Linehan WM, Morton RA, and Kim SJ (2002). Decreased expression of bone morphogenetic protein receptor type II correlates with insensitivity to BMP-6 in human renal cell carcinoma cells. Clin Cancer Res 9: 6046-6051.
  • Kim HT, Kim BC, Kim IY, Mamura M, Seong DH, Jang JJ, and Kim SJ (2002). Raloxifene, a mixed estrogen agonist/antagonist, induces apoptosis through cleavage of BAD in human bladder cancer cells. J Biol Chem 277: 32510-32515.
  • Kim IY, Lee DH, Ahn HJ, Tokunaga HJ, Song W, Devereaux LM, Jin D, Sampath TK, and Morton RA (2000). Expression of bone morphogenetic protein receptors type-IA, -IB, and –II correlates with tumor grade in human prostate cancer tissues. Cancer Res 60: 2840-2844.
Gender
  • Male